0.00
—
Close of 30 Oct 2026, in USD
About Neurobiological Technologies
Its shares trade under the ticker NTII. It has been listed since 16 February 1994. In the fiscal year to 30 June 2010, it reported revenue of $6.0m and net income of $4.9m. At that date it held total assets of $2.6m and shareholders' equity of $1.5m.
Neurobiological Technologies, Inc. manufactures biological products. The company is headquartered in San Ramon, California. On October 27, 2009, the Company’s stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company. On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 16 Feb 1994
- Employees
- 4
Leadership
Pay as last reported
- Mr. Matthew LoarActing Chief Executive and Financial Officer, Director, since 2008$345,773
- William FletcherDirector, since 2007$153,975
- Mr. John StuppinDirector, since 1987
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Neurobiological Technologies Inc (NTI) has a strong focus on research and development, consistently investing in innovative technologies and therapies.
- The company possesses a diverse and talented team of neuroscientists, biologists, and medical professionals who contribute to the success and growth of NTI.
- With several patented technologies and intellectual property rights, NTI has a competitive advantage in the neurobiological field.
Weaknesses
- One of the main weaknesses of NTI is its heavy reliance on external funding for research and clinical trials. This poses a financial risk if there are delays or difficulties in securing funding.
- The company's limited marketing and distribution capabilities result in a relatively small market reach, limiting its potential customer base and revenue generation.
- NTI faces challenges in gaining regulatory approval for its innovative therapies, which can slow down the commercialization process and increase development costs.
Opportunities
- The growing demand for neurobiological treatments presents a significant opportunity for NTI to expand its product portfolio and capture a larger market share.
- Collaborating with pharmaceutical companies, research institutions, and healthcare providers can provide NTI with access to additional resources, expertise, and potential partnerships.
- Developing strategic alliances or licensing agreements with international companies could enable NTI to enter new geographic markets and increase its global presence.
Threats
- Competition from larger, well-established pharmaceutical companies poses a threat to NTI's market position, as these companies have greater resources and established distribution networks.
- Changes in regulatory and reimbursement policies can significantly impact NTI's ability to bring its therapies to market and generate revenue.
- Emerging technologies and alternative treatment options may disrupt the neurobiological industry, forcing NTI to adapt and innovate to remain competitive.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.